Regulatory

Drug Price Regulation

The Food and Drug Administration (FDA) has two initiatives for lowering drug prices: Government Mediated Access Price (GMAP) and Maximum Drug Retail Price (MDRP).

GMAP is a mediated action made by the FDA to convince drug companies to lower the prices of the their products. The prices listed on GMAP apply only to the particular manufacturer/brand specified. Drug retailers are not allowed to sell the listed products above the GMAP.

MDRP is a government intervention by the FDA to set a maximum retail price for specific drug molecules, regardless of brand or manufacturer. Drug retailers are not allowed to sell the listed products, whether as branded or generic versions, above the MDRP.

Muramed.com is fully compliant with the GMAP and MDRP.

You may view the most current GMAP and MDRP prices on the FDA website.

VAT-Exempt Drugs

Pursuant to Republic Act No. 10963, otherwise known as "Tax Reform for Acceleration and Inclusion (TRAIN) Law," the sale of drugs prescribed for diabetes, high cholesterol and hypertension shall be VAT-exempt.

Muramed.com is fully compliant with this provision.

You may view the complete list of VAT-exempt drugs on the FDA website.

Adverse Drug Reactions

The FDA encourages consumers to vigilantly report any adverse drug reactions (ADRs) for more efficient monitoring. You may report these adverse reactions through the FDA's ADR Online Form.